DNM1L and melanoma: Interestingly, vemurafenib, a MAPK inhibitor, has been shown to inhibit dynamin-related protein 1 (DRP1) phosphorylation, reversing excessive mitochondrial fission in melanoma cells and resulting in hyper-fusion and enhancing oxidative phosphorylation and reversal of aerobic glycolysis [199].